Calcium Channel Blockers Market

Calcium Channel Blockers Market (Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine, Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others; Route of Administration: Oral and Parenteral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Calcium Channel Blockers Market Outlook 2031

  • The global industry was valued at US$ 14.5 Bn in 2022
  • It is projected to grow at a CAGR of 5.7% from 2023 to 2031 and reach more than US$ 24.0 Bn by the end of 2031

Analysts’ Viewpoint

Increase in prevalence of cardiovascular diseases, surge in geriatric population, and rise in availability of combination therapies are driving the global calcium channel blockers market. Development of newer formulations and increase in healthcare expenditure are expected to bolster market growth. Furthermore, rise in awareness among healthcare professionals and patients about the benefits of calcium channel blockers (CCBs) are propelling global calcium channel blockers market size.

Increase in adoption of combination therapies and development of newer formulations of CCBs with improved pharmacokinetic properties and fewer side effects offer lucrative opportunities to market players. Companies are focusing on development of customized CCBs that can be tailored to individual patients' needs. Rise of telemedicine and remote patient monitoring is expected to increase access to CCBs and improve patient outcomes.

However, availability of alternative treatment options, such as ACE inhibitors and beta-blockers, is likely to hamper market growth in the next few years.

Calcium Channel Blockers Market

Global Calcium Channel Blockers Market Introduction

Calcium channel blockers (CCBs) are a class of drugs used to treat various medical conditions, particularly cardiovascular diseases such as hypertension (high blood pressure) and angina (chest pain). These drugs work by blocking the entry of calcium ions into the smooth muscle cells of blood vessels, which causes the vessels to relax and dilate. This reduces blood pressure and improves blood flow, which can help to prevent heart attacks, strokes, and other serious medical events.

Calcium channels are protein pores that allow the entry of calcium ions into cells. In the cardiovascular system, calcium channels are located in the smooth muscle cells that surround blood vessels and in the heart muscle cells. When calcium ions enter these cells, they trigger muscle contraction, which could lead to increased blood pressure and reduced blood flow.

CCBs work by selectively blocking the entry of calcium ions into the smooth muscle cells of blood vessels, which causes the vessels to relax and dilate. This reduces blood pressure and improves blood flow, which can help to prevent heart attack, stroke, and other serious medical events. CCBs also have other effects on the cardiovascular system, such as reducing heart rate and improving the oxygen supply to the heart.

Rise in prevalence of cardiovascular diseases and increase in demand for safe and effective treatment options are projected to bolster global calcium channel blockers market demand. However, emergence of alternative treatment options and increase in availability of generic drugs are likely to hamper market growth in the near future.

Increase in Incidence of Cardiovascular Diseases and Hypertension

Cardiovascular diseases (CVDs) and hypertension are among the leading causes of mortality across the world, accounting for an estimated 17.9 million deaths per year, according to the World Health Organization.

Incidence of these diseases is expected to rise, as the global population ages and lifestyle factors such as poor diet, sedentary lifestyles, and stress increase. Surge in incidence of CVDs and hypertension is a major driver of the global calcium channel blockers market development.

According to the World Health Organization, hypertension affects about 1.13 billion people globally, and the number is expected to increase to 1.56 billion by 2025. Hypertension is a major risk factor for heart disease, stroke, and other complications, and calcium channel blockers drugs are among the most commonly prescribed medications for hypertension.

According to the American Heart Association, nearly 108 million adults in the U.S. have hypertension, which is approximately 45% of the population. Hypertension is also a leading cause of heart attacks, strokes, and heart failure. Similarly, the European Society of Cardiology estimates that CVDs account for 45% of all deaths in Europe, with hypertension being a major risk factor for CVDs.

The situation is similar in emerging economies such as India and China, where the incidence of hypertension and CVDs is rising rapidly. According to a report by the Indian Council of Medical Research, the prevalence of hypertension in India has increased from 20% in 2010 to 25% in 2020, affecting approximately 260 million people.

The Chinese Hypertension Control Alliance estimates that over 300 million people in China suffer from hypertension. Consequently, demand for CCB drugs is increasing in these countries, which is driving the calcium channel blockers industry in the country.

Rise of Combination Therapies in Cardiovascular Treatment

The shift toward combination therapies is one of the primary factors driving the global calcium channel blockers market value. Combination therapy involves the use of two or more drugs to treat a specific disease or condition.

Combination therapy is used in cardiovascular diseases to achieve better control of blood pressure, reduce the risk of adverse events, and improve patient outcomes. CCBs are often combined with other drugs, such as beta-blockers, diuretics, and ACE inhibitors, to treat various cardiovascular conditions, such as hypertension and angina.

Usage of combination therapies in cardiovascular diseases has been shown to be effective in several clinical trials. For example, the ACCOMPLISH trial found that a combination of the CCB amlodipine and the ACE inhibitor benazepril was more effective in reducing cardiovascular events than either drug alone.

The ALLHAT trial found that a combination of the CCB amlodipine and the ACE inhibitor lisinopril was more effective in reducing the risk of heart failure than the diuretic chlorthalidone.

Surge in usage of combination therapies is ascribed to the need to achieve better control of blood pressure, reduce the risk of adverse events, and improve patient outcomes. As more clinicians and patients become aware of the benefits of combination therapy, the demand for CCBs is expected to rise.

The calcium channel blockers market is expected to experience steady growth as more combination therapies are developed and used to treat cardiovascular diseases.

Accessibility and Cost-effectiveness of Generic Drugs Propelling Calcium Channel Blockers Market Growth

Adoption of generic drugs is a significant factor driving the calcium channel blockers industry growth. Generic drugs are cheaper alternatives to branded drugs and are bioequivalent to the original drug. The lower cost of generic drugs has made them more accessible to patients, leading to increased adoption. In the case of CCBs, generic drugs are available in various formulations, such as amlodipine, nifedipine, and diltiazem, among others.

Adoption of generic drugs has been driven by cost savings, increased accessibility, and government initiatives. Governments of several countries have implemented policies to promote the use of generic drugs, such as subsidies, pricing regulations, and incentives for physicians to prescribe generic drugs.

Adoption of generic drugs has also been driven by expiration of patents for branded drugs. When the patent for a branded drug expires, other manufacturers can produce generic versions of the drug, leading to increased competition and lower prices. In the case of CCBs, many of the patents for branded drugs have already expired or are set to expire soon, leading to increased availability of generic drugs.

Adoption of generic drugs is expected to drive the global market in the next few years. Increase in availability and adoption of generic CCBs would lead to increased market competition, lower prices, and increased access for patients. As more patients and healthcare providers switch to generic CCBs, demand for these drugs is expected to increase.

Rise in Prevalence of Hypertension

In terms of application, the hypertension segment accounted for the largest share of the global calcium channel blockers market in 2022. Hypertension, or high blood pressure, is a widespread medical condition affecting a significant portion of the global population.

According to the World Health Organization (WHO), hypertension is estimated to affect around 1.13 billion people globally. High prevalence of hypertension creates a large patient population in need of treatment, leading to a dominant market segment for calcium channel blockers.

Calcium channel blockers are often recommended as first-line treatment or as part of combination therapy for hypertension. Their efficacy in controlling blood pressure levels makes them a popular choice among healthcare professionals and patients.

Convenience and Accessibility Driving Online Pharmacies Segment

Based on distribution channel, the online pharmacies segment dominated the global market in 2022. Convenience, accessibility, cost-effectiveness, regulatory advancements, and the impact of the COVID-19 pandemic collectively contribute to the growth of the segment.

Rise of e-commerce and digital platforms has enabled patients to conveniently order their prescribed medications from the comfort of their homes. The ease of browsing through medication options, comparing prices, and placing orders on online platforms enhances the appeal of purchasing calcium channel blockers online.

Cost is a critical factor in healthcare decisions. Attractive pricing strategy adopted by online pharmacies drives consumers toward purchasing calcium channel blockers online.

Global Calcium Channel Blockers Market Regional Insights

North America dominated the global market in 2022. This is ascribed to aging population, advanced healthcare systems, leading pharmaceutical companies, and favorable regulatory environment. These factors have resulted in a large and growing market for CCBs in the region.

North America has a large population of elderly people who are more prone to conditions such as hypertension and angina, which are treated using CCBs. Prevalence of hypertension in the region is expected to increase significantly in the next few years due to changing lifestyles and rise in obesity rates, which is likely to drive demand for these medications.

North America has a well-established healthcare system that is equipped with advanced medical technologies and treatment methods. This has allowed healthcare providers to diagnose and treat conditions more effectively, including prescribing CCBs where necessary.

Favorable regulatory environment in North America encourages innovation and ensures the safety and efficacy of medications. This has attracted pharmaceutical companies to invest in the region, leading to a range of CCB options for healthcare providers and patients.

The calcium channel blockers market in Asia Pacific is expected to grow at a faster pace in the next few years. Large population, increase in healthcare expenditure, rise in prevalence of hypertension, aging population, focus on chronic disease management, and technological advancements contribute to the region's rapid market growth.

Analysis of Key Players

This report provides profiles of leading players operating in the global calcium channel blockers market. These include Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Company Inc., Novartis AG, AstraZeneca, Merck & Co. Inc., GSK plc, Bayer AG, Sun Pharmaceutical Industries Ltd., and Daiichi Sankyo Company, Limited.

These players engage in mergers & acquisitions, strategic collaborations, and new product launches to expand their presence and gain global calcium channel blockers market share.

Key Developments in Global Calcium Channel Blockers Market

  • On February 24, 2022, CMP Pharma received FDA approval for Norliqva (Amlodipine) Oral Solution. This oral liquid solution, with a concentration of 1mg/mL, is the first and only FDA-approved medication of its kind that contains the besylate salt of amlodipine, a long-acting calcium channel blocker that is commonly used to manage hypertension and angina.
  • On May 17, 2021, Milestone Pharmaceuticals, Inc. entered into an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals to develop and potentially commercialize an investigational drug Etripamil in Greater China for the treatment of paroxysmal supraventricular tachycardia (PSVT) and other cardiovascular conditions. Milestone Pharmaceuticals is focused on developing innovative cardiovascular medicines, and the partnership with Ji Xing Pharmaceuticals will allow them to expand the potential reach of Etripamil in Greater China, if approved.

The calcium channel blockers industry research report profiles the top players based on various factors including a company overview, financial summary, strategies, product portfolio, segments, and recent advancements.

Global Calcium Channel Blockers Market Snapshot

Attribute Detail

Size in 2022

US$ 14.5 Bn

Forecast (Value) in 2031

More than US$ 24.0 Bn

Growth Rate (CAGR)

5.7%

Forecast Period

2023-2031

Historical Data Available for

2017-2022

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Drug Class
    • Phenylalkylamine
    • Benzothizepine
    • Dihydropyridine
      • 1st Generation
      • 2nd Generation
      • 3rd Generation
  • Application
    • Hypertension
    • Angina
    • Arrhythmia
    • Hypertrophic Cardiomyopathy
    • Others (Raynaud's disease, etc.)
  • Route of Administration
    • Oral
    • Parenteral
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin Americas
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bausch Health Company, Inc.
  • Novartis AG
  • AstraZeneca
  • Merck & Co. Inc.
  • GSK plc
  • Bayer AG
  • Sun Pharmaceutical Industries Ltd.
  • Daiichi Sankyo Company, Limited

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global calcium channel blockers market in 2022?

The global industry was valued at US$ 14.5 Bn in 2022

How big will the calcium channel blockers industry be in 2031?

It is projected to reach more than US$ 24.0 Bn by 2031

What will be the CAGR of the global market for calcium channel blockers during the forecast period?

The CAGR is anticipated to be 5.7% from 2023 to 2031

Which was the leading drug class segment of the CCBs industry?

The dihydropyridine segment accounted for the largest share in 2022

Which region will account for major share of the CCB market during the forecast period?

North America is expected to account for leading share during the forecast period.

Who are the prominent players in the calcium channel blockers industry?

Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Company, Inc., Novartis AG, AstraZeneca, Merck & Co. Inc., GSK plc, Bayer AG, Sun Pharmaceutical Industries Ltd., and Daiichi Sankyo Company, Limited. are the prominent players in the market.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Calcium Channel Blockers Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Calcium Channel Blockers Market Analysis and Forecast, 2017-2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Disease Prevalence & Incidence Rate globally with key countries

        5.2. Key product/brand Analysis

        5.3. Pipeline Analysis

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Calcium Channel Blockers Market Analysis and Forecast, by Drug Class

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Drug Class, 2017-2031

            6.3.1. Phenylalkylamine

            6.3.2. Benzothizepine

            6.3.3. Dihydropyridine

                6.3.3.1. 1st Generation

                6.3.3.2. 2nd Generation

                6.3.3.3. 3rd Generation

        6.4. Market Attractiveness Analysis, by Drug Class

    7. Global Calcium Channel Blockers Market Analysis and Forecast, by Application

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Application, 2017-2031

            7.3.1. Hypertension

            7.3.2. Angina

            7.3.3. Arrhythmia

            7.3.4. Hypertrophic Cardiomyopathy

            7.3.5. Others (Raynaud's disease, etc.)

        7.4. Market Attractiveness Analysis, by Application

    8. Global Calcium Channel Blockers Market Analysis and Forecast, by Route of Administration

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Route of Administration, 2017-2031

            8.3.1. Oral

            8.3.2. Parenteral

        8.4. Market Attractiveness Analysis, by Route of Administration

    9. Global Calcium Channel Blockers Market Analysis and Forecast, by Distribution Channel

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast, by Distribution Channel, 2017-2031

            9.3.1. Hospital Pharmacies

            9.3.2. Retail Pharmacies

            9.3.3. Online Pharmacies

        9.4. Market Attractiveness Analysis, by Distribution Channel

    10. Global Calcium Channel Blockers Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Market Value Forecast, by Region

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness Analysis, by Region

    11. North America Calcium Channel Blockers Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Drug Class, 2017-2031

            11.2.1. Phenylalkylamine

            11.2.2. Benzothizepine

            11.2.3. Dihydropyridine

                11.2.3.1. 1st Generation

                11.2.3.2. 2nd Generation

                11.2.3.3. 3rd Generation

        11.3. Market Value Forecast, by Application, 2017-2031

            11.3.1. Hypertension

            11.3.2. Angina

            11.3.3. Arrhythmia

            11.3.4. Hypertrophic Cardiomyopathy

            11.3.5. Others (Raynaud's disease, etc.)

        11.4. Market Value Forecast, by Route of Administration, 2017-2031

            11.4.1. Oral

            11.4.2. Parenteral

        11.5. Market Value Forecast, by Distribution Channel, 2017-2031

            11.5.1. Hospital Pharmacies

            11.5.2. Retail Pharmacies

            11.5.3. Online Pharmacies

        11.6. Market Value Forecast, by Country, 2017-2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. Market Attractiveness Analysis

            11.7.1. By Drug Class

            11.7.2. By Application

            11.7.3. By Route of Administration

            11.7.4. By Distribution Channel

            11.7.5. By Country

    12. Europe Calcium Channel Blockers Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Drug Class, 2017-2031

            12.2.1. Phenylalkylamine

            12.2.2. Benzothizepine

            12.2.3. Dihydropyridine

                12.2.3.1. 1st Generation

                12.2.3.2. 2nd Generation

                12.2.3.3. 3rd Generation

        12.3. Market Value Forecast, by Application, 2017-2031

            12.3.1. Hypertension

            12.3.2. Angina

            12.3.3. Arrhythmia

            12.3.4. Hypertrophic Cardiomyopathy

            12.3.5. Others (Raynaud's disease, etc.)

        12.4. Market Value Forecast, by Route of Administration, 2017-2031

            12.4.1. Oral

            12.4.2. Parenteral

        12.5. Market Value Forecast, by Distribution Channel, 2017-2031

            12.5.1. Hospital Pharmacies

            12.5.2. Retail Pharmacies

            12.5.3. Online Pharmacies

        12.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Spain

            12.6.5. Italy

            12.6.6. Rest of Europe

        12.7. Market Attractiveness Analysis

            12.7.1. By Drug Class

            12.7.2. By Application

            12.7.3. By Route of Administration

            12.7.4. By Distribution Channel

            12.7.5. By Country/Sub-region

    13. Asia Pacific Calcium Channel Blockers Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Drug Class, 2017-2031

            13.2.1. Phenylalkylamine

            13.2.2. Benzothizepine

            13.2.3. Dihydropyridine

                13.2.3.1. 1st Generation

                13.2.3.2. 2nd Generation

                13.2.3.3. 3rd Generation

        13.3. Market Value Forecast, by Application, 2017-2031

            13.3.1. Hypertension

            13.3.2. Angina

            13.3.3. Arrhythmia

            13.3.4. Hypertrophic Cardiomyopathy

            13.3.5. Others (Raynaud's disease, etc.)

        13.4. Market Value Forecast, by Route of Administration, 2017-2031

            13.4.1. Oral

            13.4.2. Parenteral

        13.5. Market Value Forecast, by Distribution Channel, 2017-2031

            13.5.1. Hospital Pharmacies

            13.5.2. Retail Pharmacies

            13.5.3. Online Pharmacies

        13.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Market Attractiveness Analysis

            13.7.1. By Drug Class

            13.7.2. By Application

            13.7.3. By Route of Administration

            13.7.4. By Distribution Channel

            13.7.5. By Country/Sub-region

    14. Latin America Calcium Channel Blockers Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Drug Class, 2017-2031

            14.2.1. Phenylalkylamine

            14.2.2. Benzothizepine

            14.2.3. Dihydropyridine

                14.2.3.1. 1st Generation

                14.2.3.2. 2nd Generation

                14.2.3.3. 3rd Generation

        14.3. Market Value Forecast, by Application, 2017-2031

            14.3.1. Hypertension

            14.3.2. Angina

            14.3.3. Arrhythmia

            14.3.4. Hypertrophic Cardiomyopathy

            14.3.5. Others (Raynaud's disease, etc.)

        14.4. Market Value Forecast, by Route of Administration, 2017-2031

            14.4.1. Oral

            14.4.2. Parenteral

        14.5. Market Value Forecast, by Distribution Channel, 2017-2031

            14.5.1. Hospital Pharmacies

            14.5.2. Retail Pharmacies

            14.5.3. Online Pharmacies

        14.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Market Attractiveness Analysis

            14.7.1. By Drug Class

            14.7.2. By Application

            14.7.3. By Route of Administration

            14.7.4. By Distribution Channel

            14.7.5. By Country/Sub-region

    15. Middle East & Africa Calcium Channel Blockers Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Drug Class, 2017-2031

            15.2.1. Phenylalkylamine

            15.2.2. Benzothizepine

            15.2.3. Dihydropyridine

                15.2.3.1. 1st Generation

                15.2.3.2. 2nd Generation

                15.2.3.3. 3rd Generation

        15.3. Market Value Forecast, by Application, 2017-2031

            15.3.1. Hypertension

            15.3.2. Angina

            15.3.3. Arrhythmia

            15.3.4. Hypertrophic Cardiomyopathy

            15.3.5. Others (Raynaud's disease, etc.)

        15.4. Market Value Forecast, by Route of Administration, 2017-2031

            15.4.1. Oral

            15.4.2. Parenteral

        15.5. Market Value Forecast, by Distribution Channel, 2017-2031

            15.5.1. Hospital Pharmacies

            15.5.2. Retail Pharmacies

            15.5.3. Online Pharmacies

        15.6. Market Value Forecast, by Country/Sub-region, 2017-2031

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Market Attractiveness Analysis

            15.7.1. By Drug Class

            15.7.2. By Application

            15.7.3. By Route of Administration

            15.7.4. By Distribution Channel

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player - Competition Matrix (by tier and size of companies)

        16.2. Market Share Analysis, by Company, 2022

        16.3. Company Profiles

            16.3.1. Pfizer, Inc.

                16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.1.2. Product Portfolio

                16.3.1.3. Financial Overview

                16.3.1.4. SWOT Analysis

                16.3.1.5. Strategic Overview

            16.3.2. Teva Pharmaceutical Industries Ltd.

                16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.2.2. Product Portfolio

                16.3.2.3. Financial Overview

                16.3.2.4. SWOT Analysis

                16.3.2.5. Strategic Overview

            16.3.3. Bausch Health Company, Inc.

                16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.3.2. Product Portfolio

                16.3.3.3. Financial Overview

                16.3.3.4. SWOT Analysis

                16.3.3.5. Strategic Overview

            16.3.4. Novartis AG

                16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.4.2. Product Portfolio

                16.3.4.3. Financial Overview

                16.3.4.4. SWOT Analysis

                16.3.4.5. Strategic Overview

            16.3.5. AstraZeneca

                16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.5.2. Product Portfolio

                16.3.5.3. Financial Overview

                16.3.5.4. SWOT Analysis

                16.3.5.5. Strategic Overview

            16.3.6. Merck & Co. Inc.

                16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.6.2. Product Portfolio

                16.3.6.3. Financial Overview

                16.3.6.4. SWOT Analysis

                16.3.6.5. Strategic Overview

            16.3.7. GSK plc

                16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.7.2. Product Portfolio

                16.3.7.3. Financial Overview

                16.3.7.4. SWOT Analysis

                16.3.7.5. Strategic Overview

            16.3.8. Bayer AG

                16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.8.2. Product Portfolio

                16.3.8.3. Financial Overview

                16.3.8.4. SWOT Analysis

                16.3.8.5. Strategic Overview

            16.3.9. Sun Pharmaceutical Industries Ltd.

                16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.9.2. Product Portfolio

                16.3.9.3. Financial Overview

                16.3.9.4. SWOT Analysis

                16.3.9.5. Strategic Overview

            16.3.10. Daiichi Sankyo Company, Limited

                16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.10.2. Product Portfolio

                16.3.10.3. Financial Overview

                16.3.10.4. SWOT Analysis

                16.3.10.5. Strategic Overview

    List of Tables

    Table 01. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

    Table 02. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 03. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 04. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 05. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Region, 2017-2031

    Table 06. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

    Table 07. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 08. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 09. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 10. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country, 2017-2031

    Table 11. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

    Table 12. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 13. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 14. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 15. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 16. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

    Table 17. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 18. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 19. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 20. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 21. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

    Table 22. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 23. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 24. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 25. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 26. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

    Table 27. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031

    Table 28. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

    Table 29. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    Table 30. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    List of Figures

    Figure 01. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031

    Figure 02. Global Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 03. Global Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 04. Global Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031

    Figure 05. Global Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031

    Figure 06. Global Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 07. Global Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 08. Global Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 09. Global Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 10. Global Calcium Channel Blockers Market Value Share Analysis, by Region, 2022 and 2031

    Figure 11. Global Calcium Channel Blockers Market Attractiveness Analysis, by Region, 2023-2031

    Figure 12. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031

    Figure 13. North America Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 14. North America Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 15. North America Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031

    Figure 16. North America Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031

    Figure 17. North America Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 18. North America Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 19. North America Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 20. North America Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 21. North America Calcium Channel Blockers Market Value Share Analysis, by Country, 2022 and 2031

    Figure 22. North America Calcium Channel Blockers Market Attractiveness Analysis, by Country, 2023-2031

    Figure 23. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031

    Figure 24. Europe Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 25. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 26. Europe Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031

    Figure 27. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031

    Figure 28. Europe Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 29. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 30. Europe Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 31. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 32. Europe Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 33. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 34. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031

    Figure 35. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 36. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 37. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031

    Figure 38. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031

    Figure 39. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 40. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 41. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 42. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 43. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 44. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 45. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031

    Figure 46. Latin America Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 47. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 48. Latin America Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031

    Figure 49. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031

    Figure 50. Latin America Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 51. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 52. Latin America Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 53. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 54. Latin America Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 55. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 56. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031

    Figure 57. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031

    Figure 58. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031

    Figure 59. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031

    Figure 60. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031

    Figure 61. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031

    Figure 62. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031

    Figure 63. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031

    Figure 64. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031

    Figure 65. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 66. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 67. Global Calcium Channel Blockers Market Share Analysis, by Company, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved